Granulocytic sarcoma preceding AML M0 and the diagnostic value of CD34

E Astall, H Yarranton, J Arno, R Marcus

Abstract
Granulocytic sarcoma with no demonstrable abnormalities in the peripheral blood or bone marrow is a rare but recognised initial manifestation of acute myeloid leukaemia and has led to diagnostic difficulties in some cases. A lymph node excisional biopsy from a patient presenting with cervical lymphadenopathy, a mediastinal mass, and a normal peripheral blood picture was reported to have features suggesting a T cell non-Hodgkin lymphoma, for which she was subsequently treated. However, 10 months later the patient developed acute myeloid leukaemia, FAB classification M0. The initial lymph node biopsy was reviewed and further immunohistochemical studies using antibodies against CD34 led to a revised diagnosis of primary granulocytic sarcoma.

Keywords: granulocytic sarcoma; CD34; lymphoma

Granulocytic sarcomas are extramedullary tumours composed of immature myeloid cells. They are usually associated with acute myeloid leukaemia (AML) and less commonly with blastic transformation of chronic myeloid leukaemia and myelodysplastic syndromes. In the majority of cases the diagnosis is made at presentation or during the course of AML but rarely the condition may occur as an isolated entity, which precedes the leukaemic phase by months or years.1 In such cases, granulocytic sarcomas may be misdiagnosed as lymphoma.2

This report illustrates the difficulties in such a case where the standard panel of special stains including chloroacetate esterase and lysozyme were negative; only subsequently was an antibody against early haematopoietic markers such as CD34 employed and found to be of diagnostic value.

Case report
In December 1996, a previously fit 42 year old woman presented to her local hospital with a one month history of a soft tissue swelling in her neck. Examination revealed a mass of lymph nodes in the left supraclavicular fossa (8 x 10 cm) and a further mass (3 x 4 cm) in the right anterior triangle of the neck. There was no palpable hepatosplenomegaly.

Laboratory investigations showed haemoglobin 14 g/dl, white blood cell count 6.5 x 10^9/litre (normal differential), and platelets 402 x 10^9/litre. The biochemical profile was unremarkable. Computed tomography revealed additional superior mediastinal and right paratracheal lymphadenopathy.

A lymph node (1.5 x 1 x 1 cm) was excised from the left cervical region. This tissue was processed for routine histopathological examination only. No fresh tissue was submitted for cytogenetic analysis. The features of the lymph node were eccentric and a diffuse infiltrate of medium sized cells was present throughout; these extended beyond the capsule. The cells of the infiltrate had oval nuclei with stippled chromatin, occasional small nucleoli, and scanty cytoplasm (fig 1). Among them, cells undergoing apoptosis were conspicuous and occasional mitotic figures were present. The infiltrate was intimately mixed with small lymphocytes, which appeared unremarkable.

Initially, the impression was that the infiltrate consisted of lymphoid cells, and immunohistochemical staining showed them to be positive for CD45 and CD43, but antibodies for specific T cell and B cells antigens were negative. Although follicles as such were absent, immunostaining revealed that the infiltrate tended to spare B cell areas of the node. A possible diagnosis of acute myeloid leukaemia was entertained but CD15, chloroacetate esterase, and lysozyme staining all proved negative. No cytoplasmic granules could be recognised in a thin Giemsa section. In view of these findings the lymph node was referred for a further opinion. At the second laboratory, similar immunostaining results were obtained but the suggestion was made that it might represent an unusual type of peripheral T cell lymphoma since the infiltrate was CD43 positive. A bone marrow aspirate and trephine taken a month...
later showed normal cellularity with no lymphomatous involvement.

In the absence of any other diagnosis, the patient was treated with six three weekly cycles of CHOP chemotherapy (cyclophosphamide 750 mg/m², vincristine 1.4 mg/m², doxorubicin 50 mg/m² all on day 1, and oral prednisolone 100 mg daily for five days). Repeat computed tomography showed partial remission and she subsequently received involved field radiotherapy, 35 Gy in 17 fractions.

Ten months after her initial presentation she was seen with a one month history of sore throat, dyspnoea, cough productive of white sputum, and occasional epistaxis. Examination revealed pallor, a systolic flow murmur, and mild hepatosplenomegaly but no lymphadenopathy.

Her haemoglobin had fallen to 5.9 g/dl, her white blood count was 123 × 10⁹/litre (blasts 112 × 10⁹/litre), and her platelet count 19 × 10⁹/litre.

A bone marrow aspiration now showed that the marrow was entirely replaced by small undifferentiated blasts with a high nucleus to cytoplasm ratio. Flow cytometry studies on the bone marrow aspirate showed the following cell markers: CD7 86%, CD33 79%, CD34 77%, CD45 74%, and CD13 68%, while CD3, myeloperoxidase, and TdT were negative, CD43 74%, and CD13 68%, while CD3, myeloperoxidase, and TdT were negative, CD45 74%, and CD13 68%. Flow cytometry studies on the bone marrow aspirate showed the following cell markers: CD7 86%, CD33 79%, CD34 77%, CD45 74%, and CD13 68%, while CD3, myeloperoxidase, and TdT were negative, CD43 74%, and CD13 68%. Flow cytometry studies on the bone marrow aspirate showed the following cell markers: CD7 86%, CD33 79%, CD34 77%, CD45 74%, and CD13 68%, while CD3, myeloperoxidase, and TdT were negative.

A bone marrow trephine performed simultaneously with the aspirate showed a packed marrow composed of a uniform population of moderately sized cells with oval nuclei, finely dispersed chromatin, and one or two small nucleoli. The cytoplasm was variable and granules were inconspicuous.

Following the diagnosis of AML, the initial lymph node biopsy was reviewed. Further immunostaining performed in view of the flow cytometry findings showed that the infiltrate in the node stained strongly positive for CD34 (fig 2), suggesting that the cells were of early haematopoietic origin. It was therefore concluded that this patient had initially presented with a minimally differentiated granulocytic sarcoma that had been misdiagnosed as a lymphoma, and had developed typical AML M0 10 months later.

Treatment was started with induction chemotherapy consisting of high dose cytarabine (3 g/m² twice daily on days 1, 3, and 5). An anthracycline based regimen was initially avoided in view of her previous anthracycline treatment. A bone marrow aspirate 18 days later showed refractory disease. After normal cardiac function was ascertained by echocardiography, her chemotherapy was changed to ADE (cytarabine 100 mg/m², days 1–10; daunorubicin 50 mg/m², days 1, 3, and 5; and etopside 100 mg/m², days 1–5). She achieved complete remission after this course of chemotherapy. This was followed by consolidation chemotherapy with a further course of ADE and then MACE (amascrine 100 mg/m², cytarabine 200 mg/m², and etopside 100 mg/m², days 1–5).

Four weeks after her MACE chemotherapy she was readmitted in cardiac failure, and echocardiography showed features suggestive of a cardiomyopathy. She developed renal failure and died three days later. Necropsy findings were a dilated cardiomyopathy consistent with anthracycline toxicity; there was no evidence of a leukemic relapse.

Discussion

Although rare, granulocytic sarcoma preceding acute myeloid leukaemia is a recognised phenomenon. Clinically and histologically, such a presentation may mimic an aggressive non-Hodgkin lymphoma. Granulocytic sarcomas, especially when minimally differentiated, may be difficult to distinguish from lymphoma. In particular, they often lack characteristic myeloid features such as demonstrable chloroacetate esterase activity. In such cases, routine immunohistochemical analysis may produce conflicting results, making a diagnosis difficult. The use of antibodies against CD34, which is expressed in acute myeloid leukaemias, may provide a useful addition to a panel of antibodies in these unusual cases, facilitating identification of cells of myeloid origin and excluding lymphoma.

CD34 is a molecule of unknown function expressed on haematopoietic stem cells, vascular endothelium, and dendritic cells. CD34 is not expressed in lymphomas or mature peripheral blood cells but is expressed on leukemic cells of both myeloid (including granulocytic sarcoma) and lymphoid origin. In one study, approximately 30% of well and poorly differentiated granulocytic sarcomas were CD34 positive, but in cases of blast type granulocytic sarcoma, positivity rose to 60%.

In our case of minimally differentiated granulocytic sarcoma, even though chloroacetate esterase and lysozyme were negative, perhaps the CD34 positivity should have suggested the possibility of myeloid leukaemia rather than a lymphoma, as other evidence did not support the latter. CD34 is known to be...
expressed on myeloid tumours and some monocytic tumours (as well as the majority of diffuse low grade B cell lymphomas).

Granulocytic sarcoma preceding AML is rare, with only 154 cases reported between 1965 and 1995. Nearly half of these were initially misdiagnosed as lymphoma. The FAB types of the subsequent AML in the majority of cases are either M1 or M2; however, M4, M5, and M7 have been described. In our case, the granulocytic sarcoma preceded AML of FAB type M0, which to our knowledge has not been reported previously.

Granulocytic sarcomas may resemble lymphoma morphologically, but the lack of expected immunohistochemical markers should alert the pathologist to the possibility of a granulocytic sarcoma. In such cases, the addition of CD34 to the standard panel of immunohistochemistry may help to elucidate the correct diagnosis.

Granulocytic sarcoma preceding AML M0 and the diagnostic value of CD34.

E Astall, H Yarranton, J Arno and R Marcus

doi: 10.1136/jcp.52.9.705

Updated information and services can be found at:
[http://jcp.bmj.com/content/52/9/705](http://jcp.bmj.com/content/52/9/705)

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
[http://group.bmj.com/group/rights-licensing/permissions](http://group.bmj.com/group/rights-licensing/permissions)

To order reprints go to:
[http://journals.bmj.com/cgi/reprintform](http://journals.bmj.com/cgi/reprintform)

To subscribe to BMJ go to:
[http://group.bmj.com/subscribe/](http://group.bmj.com/subscribe/)